News

IMB researchers have found that the New Zealand stinging tree produces toxins that could hold clues for future pain medication.

IMB's Professor David Craik has been elected as a Fellow of the oldest scientific society in the world for his outstanding contribution to science.

A potentially life-saving treatment containing venom from one of the world’s deadliest spiders is one step closer to human trials, thanks to a $23 million investment in a Brisbane start-up.

IMB researchers have used genetics to show that a daily coffee causes no increased risk to pregnancy.

Dr Melanie Oey is harnessing the power of microalgae to speed up wound healing, shaking up the industry in the process.

An IMB PhD student will use a prestigious foreign exchange scholarship to progress his work on developing medicines from nature. Isaac Tucker is harnessing molecules found in the venom of Australian spiders to develop treatments for neurological and gastrointestinal diseases.

Finding a genetic link between endometriosis and ovarian cancer will increase the understanding of both diseases.

Australian bull ants have evolved a venom molecule that has implications for sufferers of long-term pain.

IMB virologist Dr Larisa Labzin answers questions on long COVID and whether scientists could eventually develop a vaccine against all COVID-19 variants.

An investigation into why disruption of the circadian clock is associated with disease uncovered 'feminisation' protecting the liver.

Disarming superbugs that can cause deadly infections is the focus of a powerful database now housed at The University of Queensland.

A new study has challenged the growing popular belief that the gut microbiome drives autism.

IMB researchers will tackle fundamental questions with $4.5 million of support from the NHMRC Idea Grants, including the researching devastating neural tube defects.

The SARS-CoV-2 virus does not infect blood vessels, despite the high risk of blood clots, IMB researchers have confirmed.

A pathway discovered in cancer cells will inform future targeted therapies.

People with higher genetic risk of clinical depression are more likely to have physical symptoms such as chronic pain, fatigue and migraine.

Australia may soon have the jump on cane toads after a not-for-profit was granted an exclusive licence to market an IMB-designed bait for the invasive pests.

Drug discovery research at IMB has been given a $12.9 million boost of Australian Government funding, to push the boundaries for more targeted, efficient new medicines.

For every life-saving antibiotic introduced, bacteria have developed varying levels of resistance, replicating and adapting faster than human cells.

Researchers are daring to discover urgently needed new drugs and therapies from one of the most painful plants in Australia.